Introduction
hepatitis B, Simulated HIV vaccine, liver cirrhosis, primary liver cancer, KPs living with HIV show varied HBV
HEPATITIS B, VIRUS, CHRONIC INFECTION, LIVER CIRRHOSIS, PRIMARY LIVER CANCER
Worldwide in 2019, an estimated 1.5 million people acquired hepatitis B virus (HBV), a chronic infection of public health concern because it is complicated by liver cirrhosis and primary liver cancer in 20–30% of individuals [Recent surveys done among KPs living with HIV show varied HBV prevalence, including 4.0% from a cross-sectional survey among female sex workers (FSWs), men who have sex with men (MSM) and injection drug users (IDUs) in South Africa (prevalence similar across KPs) [Simulated HIV vaccine efficacy trials (SiVETs) using licensed Hepatitis B vaccine (ENGERIX-B™ GlaxoSmithKline Biologicals Rixensart, Belgium and EUVAX by SANOFI Pasteur) to approximate the vaccination schedules and conditions of an HIV vaccine trial have been conducted among KPs in SSA. The SiVETs reported on vaccination completion and retention [